One year after Zarxio approval, future of biosimilars remains unclear 

It's been a year since federal regulators approved the first biosimilar drug for sale in the U.S., a moment many believed marked the beginning of a new market expected to foster competition between some of healthcare's most expensive drugs, and with it, lower prices.  READ MORE